Status:

COMPLETED

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Lead Sponsor:

Biotest

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The study is conducted in order to find out if repeated doses of the monoclonal (artificially manufactured) antibody BT061 can help arthritis patients whose disease does not sufficiently respond to a ...

Detailed Description

Patients showing active rheumatoid arthritis according to ACR criteria despite at least 6 months of treatment with methotrexate fulfilling all other inclusion criteria including written informed conse...

Eligibility Criteria

Inclusion

  • Patients with active Rheumatoid Arthritis (RA) according to 1987 revised ACR criteria with functional class II-III
  • Disease activity at screening and baseline (more than 6 swollen joint count; more than 6 tender joint count; elevat. of CRP or ESR)
  • Duration of RA more than 12 month
  • History of at least one disease-modifying anti-rheumatic drug (DMARD) with an inadequate response despite more than 3 month of treatment
  • MTX treatment at least 6 month with a stable dose at least 15mg MTX
  • Patients could continue at more than daily 7,5mg of prednisone or equivalent stable dose at least 6 weeks prior baseline
  • Written Informed Consent

Exclusion

  • Treatment with traditional DMARDs apart from MTX 12 weeks prior to baseline and DMARD leflunomide 24 weeks
  • Treatment with any biologics other than TNF-α inhibitors (e.g. abatacept, rituximab, tocilizumab, anakinra)
  • treatment with any TNF-α inhibitor within 5 elimination half-lives prior baseline and during the study
  • Clinical non-response to more than one of TNF-α inhibitor exceeding adequate treatment duration

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

127 Patients enrolled

Trial Details

Trial ID

NCT01481493

Start Date

December 1 2010

End Date

November 1 2013

Last Update

February 20 2015

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Study Site

Ostrava, Czechia

2

Study Site

Prague, Czechia

3

Study Site

Uherské Hradiste, Czechia

4

Study Site

Zlín, Czechia